Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ximing Tang

Showing results (51-60 of 86) with videos related to

Pageof 9
Sort By:
Molecular Cancer Therapeutics|July 22, 2017
JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non-Small Cell Lung CancerKazuhiko Shien, Vassiliki A Papadimitrakopoulou, Dennis Ruder, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2015
KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI VandetanibMonique B Nilsson, Uma Giri, Jayanthi Gudikote, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2018
Validation of the 12-gene Predictive Signature for Adjuvant Chemotherapy Response in Lung CancerYang Xie, Wei Lu, Shidan Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 25, 2024
Antitumor Activity and Biomarker Analysis for TROP2 Antibody-Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft ModelsFunda Meric-Bernstam, Erkan Yuca, Kurt W Evans, et al.
Plos One|October 15, 2009
Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cellsJunichi Soh, Naoki Okumura, William W Lockwood, et al.
Nature Cancer|May 13, 2025
CHD1 loss reprograms SREBP2-driven cholesterol synthesis to fuel androgen-responsive growth and castration resistance in SPOP-mutated prostate tumorsFeiyu Chen, Haoyan Li, Yin Wang, et al.
Biorxiv : the Preprint Server for Biology|February 17, 2023
STAT3 protects HSCs from intrinsic interferon signaling and loss of long-term blood-forming activityBhakti Patel, Yifan Zhou, Rachel L Babcock, et al.
Oncogene|September 29, 2021
Prostate cancer castrate resistant progression usage of non-canonical androgen receptor signaling and ketone body fuelEstefania Labanca, Juan Bizzotto, Pablo Sanchis, et al.
Cancer Research|July 5, 2011
Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapyFei Yang, Ximing Tang, Erick Riquelme, et al.
Surgery|November 6, 2018
Genetic characterization of medullary thyroid cancer in childhood survivors of the Chernobyl accidentSarah B Fisher, Gilbert J Cote, Jacquelin H Bui-Griffith, et al.
Pageof 9

Showing results (51-60 of 86) with videos related to

Sort By:
Pageof 9
Molecular Cancer Therapeutics|July 22, 2017
JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non-Small Cell Lung CancerKazuhiko Shien, Vassiliki A Papadimitrakopoulou, Dennis Ruder, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2015
KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI VandetanibMonique B Nilsson, Uma Giri, Jayanthi Gudikote, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2018
Validation of the 12-gene Predictive Signature for Adjuvant Chemotherapy Response in Lung CancerYang Xie, Wei Lu, Shidan Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 25, 2024
Antitumor Activity and Biomarker Analysis for TROP2 Antibody-Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft ModelsFunda Meric-Bernstam, Erkan Yuca, Kurt W Evans, et al.
Plos One|October 15, 2009
Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cellsJunichi Soh, Naoki Okumura, William W Lockwood, et al.
Nature Cancer|May 13, 2025
CHD1 loss reprograms SREBP2-driven cholesterol synthesis to fuel androgen-responsive growth and castration resistance in SPOP-mutated prostate tumorsFeiyu Chen, Haoyan Li, Yin Wang, et al.
Biorxiv : the Preprint Server for Biology|February 17, 2023
STAT3 protects HSCs from intrinsic interferon signaling and loss of long-term blood-forming activityBhakti Patel, Yifan Zhou, Rachel L Babcock, et al.
Oncogene|September 29, 2021
Prostate cancer castrate resistant progression usage of non-canonical androgen receptor signaling and ketone body fuelEstefania Labanca, Juan Bizzotto, Pablo Sanchis, et al.
Cancer Research|July 5, 2011
Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapyFei Yang, Ximing Tang, Erick Riquelme, et al.
Surgery|November 6, 2018
Genetic characterization of medullary thyroid cancer in childhood survivors of the Chernobyl accidentSarah B Fisher, Gilbert J Cote, Jacquelin H Bui-Griffith, et al.
Pageof 9